Overall, detailed characterization of the intra-tumor expression of CD226, CD155, TIGIT, CD112, and CD112R can provide critical insights into the tumor immune landscape, supporting patient selection for more effective, tailored immunotherapeutic strategies. This evidence concerns the gene PVR and neoplasm.